- Home
- / Sutro Biopharma
Sutro Biopharma
Stock Price
$3.5
2024-10-29
Market Capitalization
$294.3 M
2024-10-29
Revenue
$102.5 M
FY, 2025
Sutro Biopharma Summary
Company Summary
- Overview
- Sutro Biopharma is a clinical-stage company that develops cancer therapeutics. It offers XpressCF, technology that designs and manufactures therapeutic proteins using cell-free protein synthesis; and XpressCF+, a platform that develops therapeutic proteins that contain non-natural amino acids.
- Type
- Public
- Status
- Active
- Founded
- 2003
- HQ
- South San Francisco, CA, US | view all locations
- Website
- http://www.sutrobio.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Kwadwo Bediako, Vice President, Global Program Leader
Edward Albini, Chief Financial Officer
William F. Bleker, Vice President, Medical Safety and Pharmacovigilance
Operating MetricsView all
Facility Space Leased, sq. ft.
145.1K
FY, 2023
LocationsView all
1 location detected
South San Francisco, CA HQ
United States
111 Oyster Point Blvd
Sutro Biopharma Financials
Summary Financials
- Revenue (Q1, 2026)
- $14.5M
- Net income (Q1, 2026)
- ($38.5M)
- Cash (Q1, 2026)
- $73.7M
- EBIT (Q1, 2026)
- ($29.7M)
- Enterprise value
- $234.2M